Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment

NCT05858203 | Unknown

• 1 other identifier: RS1442/20
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 2

Brief Summary

Multiple myeloma (MM) is a haematological malignancy characterized by the accumulation of proliferating antibody producing plasma cells in the bone marrow. In the last few years many studies have emphasized the biological complexity and heterogeneity of MM as a result of both genetic and epigenetic aberrations. Che-1/AATF (Che-1) is a transcriptional cofactor involved in cell cycle regulation, apoptosis, DNA damage and stress response. it can be hypothesized that Che-1 might contribute to the establishment of the MM malignant phenotype by sustaining global transcription through its ability to modulate chromatin accessibility. The prospective study on MM human samples aims to understand the involvement of Che-1 in the transcriptional regulation and chromatin remodeling during the pathology. To this goal the main objectives are:

• Characterization of Che-1's role in chromatin remodeling and global gene expression
• Study in vivo and in vitro of Che-1 involvement in MM tumorigenesis
• Evaluation of Che-1 as a possible therapeutic target

Conditions

Multiple Myeloma

Outcome Measures

Primary Outcomes (1)

• Che-1 involvement in MM tumorigenesis

  Characterization of Che-1's role in chromatin remodeling and global gene expression

  About 2 years

Interventions

ATAC-seq and ChIP-seq OTHER

CD138+ cells will be isolated from the bone marrow of MM patients and will be subjected to ATAC-seq and ChIP-seq analyses, by useing specific antibodies, to better understand the involvment of Che-1 in MM tumorogenesis.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

MM Patients

You may qualify if:

• MM Patients

Sponsors & Collaborators

• Regina Elena Cancer Institute: lead

Study Sites (2)

Regina elena Cancer Institute

Roma, 00144, Italy

ACTIVE NOT RECRUITING

"Regina Elena" National Cancer Institute

Rome, 00144, Italy

RECRUITING

MeSH Terms

Conditions

Multiple Myeloma

Interventions

Chromatin Immunoprecipitation Sequencing

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Chromatin Immunoprecipitation; Genetic Techniques; Investigative Techniques; High-Throughput Nucleotide Sequencing; Sequence Analysis; Sequence Analysis, DNA; Immunoprecipitation; Immunologic Techniques

Central Study Contacts

Maurizio fanciulli, PhD

CONTACT

+39 06 52662800; maurizio.fanciulli@ifo.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 24, 2023
• First Posted: May 15, 2023
• Study Start: December 22, 2020
• Primary Completion: March 21, 2023
• Study Completion: December 31, 2025
• Last Updated: May 15, 2023

Record last verified: 2023-03

Locations

IT (2)